Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Ark Therapeutics presents new neuropilin-1 antagonists

March 31, 2011

New steroid sulfatase/aromatase inhibitors reported by Sterix

March 31, 2011

SMO inhibitors reported by Pfizer for use in cancer

March 31, 2011

OriBase Pharma identifies agent for BCR/ABL T315I mutant CML

March 31, 2011

Eisai and Minophagen complete Japanese license agreement for CTCL treatment bexarotene

March 30, 2011

The University of Manchester presents novel kinase inhibitors

March 30, 2011

IMD-0354 exhibits proapoptotic effects in CLL cells in vitro by targeting NF-kappa-B

March 30, 2011

Ono and OncoTherapy enter license agreement for therapeutic peptide vaccines for cancer

March 29, 2011

Onyx to modify phase III FOCUS study of carfilzomib in relapsed and refractory myeloma

March 29, 2011

Data Monitoring Committee recommends continuing belinostat trial

March 29, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...